Humira licensed for paediatric Crohn's

The licensed indications for Humira (adalimumab) have been extended to include treatment of severe active Crohn's disease in children aged 6 years and older.

In addition to its Crohn's indication (pictured), Humira is also licensed for ulcerative colitis  | SCIENCE PHOTO LIBRARY
In addition to its Crohn's indication (pictured), Humira is also licensed for ulcerative colitis | SCIENCE PHOTO LIBRARY

Humira (adalimumab) can be prescribed in children who have had an inadequate response to conventional therapy including primary nutrition therapy, a corticosteroid and an immunomodulator, or who are intolerant to or have contraindications for such therapies.

Dosing recommendations

Children weighing less than 40kg should receive an initial dose of 40mg followed by a 20mg dose two weeks later. Dosing should then be continued at 20mg on alternate weeks, increasing to 20mg once weekly if necessary. In children weighing 40kg or more the recommended dose is 80mg initially followed by 40mg two weeks later, then 40mg every one or two weeks. Humira is given by subcutaneous injection.

View Humira record

Further information: AbbVie Ltd

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases